文献速递前列腺癌

微超声与MRI靶向活检在前列腺癌诊断中的系统评价与荟萃分析

Micro-ultrasonography- vs MRI-targeted biopsy in prostate cancer: Updated systematic review and meta-analysis.
PubMed 文献 · BJU Int · 2026-04-16

该系统评价与荟萃分析纳入22项研究,比较微超声靶向活检与MRI靶向活检对临床显著前列腺癌的检出率和诊断准确性。微超声靶向活检检出2043例中2037例,MRI靶向活检检出2043例,合并检出比1.04(95%CI 0.95-1.15),敏感性和特异性相近,提示两种方法诊断效能相当。

要点

  • 微超声靶向活检与MRI靶向活检检出临床显著前列腺癌的合并检出比为1.04(95%CI 0.95-1.15)。
  • 微超声靶向活检 pooled 敏感性0.88、特异性0.25;MRI靶向活检分别为0.81、0.17。
  • 两种方法的SROC曲线重叠(AUC:微超声0.658,MRI 0.547),诊断准确性相当。

核心结论

  • 微超声靶向活检对临床显著前列腺癌的检出率和诊断准确性可与MRI靶向活检相媲美。
  • 鉴于实时成像能力、可及性和潜在工作流程优势,微超声靶向活检可能成为当代前列腺癌诊断路径中有价值的补充工具。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、EMBASE和ClinicalTrials.gov(2025年7月4日检索,2025年8月5日更新),无语言和日期限制。
  • 纳入22项随机和观察性研究,比较微超声靶向活检与MRI靶向活检(±系统活检)在疑似前列腺癌或主动监测男性中的诊断效能。
  • 临床显著前列腺癌定义为Gleason分级分组≥2;采用QUADAS-2工具评估质量,GRADE框架评级证据确定性。

主要发现

  • 共纳入22项研究,微超声靶向活检组5581例,MRI靶向活检组5937例。
  • 微超声靶向活检检出2037例临床显著前列腺癌,MRI靶向活检检出2043例。
  • 合并检出比(微超声 vs MRI)为1.04(95%CI 0.95-1.15;I2=61.1%)。
  • 微超声靶向活检 pooled 敏感性/特异性为0.88/0.25,MRI靶向活检为0.81/0.17。
  • SROC曲线重叠(AUC:微超声0.658,MRI 0.547);Meta回归显示模态对敏感性(P=0.192)或特异性(P=0.257)无显著影响;Egger检验提示无显著发表偏倚(P=0.848)。

关键数值与推荐

  • 临床显著前列腺癌定义:Gleason分级分组≥2。
  • 合并检出比1.04(95%CI 0.95-1.15;I2=61.1%)。
  • 微超声靶向活检敏感性0.88、特异性0.25;MRI靶向活检敏感性0.81、特异性0.17。
  • SROC AUC:微超声0.658,MRI 0.547。
  • Meta回归敏感性P=0.192,特异性P=0.257;Egger检验P=0.848。

临床怎么用

  • 微超声靶向活检可作为MRI靶向活检的补充工具用于前列腺癌诊断路径。
  • 其真实成像能力和可及性可能优化工作流程,但需进一步成本效果研究明确临床角色。

局限性

  • 纳入研究存在异质性(I2=61.1%)。
  • 需进一步开展成本效果研究以明确微超声靶向活检在临床实践中的定位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To refine prostate cancer (PCa) pathways by comparing micro-ultrasonography-targeted biopsy (micro-US-TBx) with magnetic resonance imaging (MRI)-TBx for detecting clinically significant PCa (csPCa) and by evaluating diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value). METHODS: The Medical Literature Analysis and Retrieval System Online (MEDLINE; PubMed), Excerpta Medica dataBASE (EMBASE), and ClinicalTrials.gov were searched on 4 July 2025 and updated 5 August 2025, without language/date limits. Eligible randomised and observational studies compared micro-US-TBx vs MRI-TBx (± systematic biopsy) in men with suspected PCa or on active surveillance; csPCa was Gleason Grade Group ≥2. Two reviewers screened/extracted per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines; quality was assessed with the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Detection ratios (DRs) were pooled with random-effects models; diagnostic accuracy used a bivariate random-effects model from 2 × 2 tables. Certainty of evidence was rated with the Grading of Recommendations, Assessment, Development, and Evaluation framework. RESULTS: A total of 22 studies (micro-US-TBx = 5581; MRI-TBx = 5937) were included. Micro-US-TBx detected 2037 csPCa cases and MRI-TBx 2043. The pooled DR (micro-US-TBx vs MRI-TBx) was 1.04 (95% confidence interval 0.95-1.15; I2 = 61.1%). Pooled sensitivity/specificity were 0.88/0.25 for micro-US-TBx and 0.81/0.17 for MRI-TBx. Summary receiver operating characteristic curves overlapped (area under the curve: micro-US, 0.658; MRI, 0.547). Meta-regression found no significant modality effect on sensitivity (P = 0.192) or specificity (P = 0.257). Egger's test indicated no meaningful publication bias (P = 0.848). CONCLUSION: The micro-US-TBx demonstrated csPCa detection and diagnostic accuracy comparable to MRI-TBx. Given its real-time imaging capability, accessibility, and potential workflow advantages, micro-US-TBx may represent a valuable complementary tool within contemporary PCa diagnostic pathways. Further cost-effectiveness studies are warranted to better define its role in clinical practice.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Micheleto JPC, Suzuki TÁ, Santos LA, et al. Micro-ultrasonography- vs MRI-targeted biopsy in prostate cancer: Updated systematic review and meta-analysis. BJU Int. 2026. PMID: 41989063. doi:10.1111/bju.70270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。